Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 3:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 9,123 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Recurrent Neoplasm Clear all

Conditions: Lymphoma
Interventions: filgrastim, rituximab, sargramostim, carmustine, cyclophosphamide, etoposide, adjuvant therapy, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 70 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions: bryostatin 1, cisplatin, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Duarte, California

Conditions: Brain Tumors
Interventions: Not listed
Lead sponsor: Wayne State University; Other
Eligibility: 13 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Lung Cancer, Lymphoma, Pancreatic Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: fluorouracil, gemcitabine hydrochloride, leucovorin calcium; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Recurrent Head and Neck Carcinoma
Interventions: Intensity-Modulated Radiation Therapy, Proton Radiation, Stereotactic Body Radiation Therapy; Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
Interventions: arsenic trioxide; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 16 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 94
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more

Conditions: Grade 1 Meningioma, Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma, Unresectable Meningioma
Interventions: Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Computed Tomography, Biospecimen Collection, Single Photon Emission Computed Tomography; Radiation · Drug · Procedure + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2032
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions: 5-azacytidine (5-aza) maintenance therapy after transplant; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hodgkin Lymphoma
Interventions: Everolimus (RAD001); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 16
States / cities: Los Angeles, California • Greenwood Village, Colorado • Orlando, Florida + 13 more

Conditions: Ovarian Cancer
Interventions: oglufanide disodium; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Metastatic Malignant Female Reproductive System Neoplasm, Platinum-Resistant Malignant Female Reproductive System Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Refractory Malignant Female Reproductive System Neoplasm
Interventions: Durvalumab, Internal Radiation Therapy, Tremelimumab; Biological · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prostate Cancer
Interventions: Gefitinib plus etoposide; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 120 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Lymphoma
Interventions: TLN-254; Drug
Lead sponsor: Treeline Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 4
States / cities: Stanford, California • St Louis, Missouri • New York, New York + 1 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: busulfan, Cyclophosphamide, VP-16, Fractionated Total Body Irradiation (FTBI); Drug · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 15 Years to 55 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2007
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Lymphoma
Interventions: filgrastim, rituximab, sargramostim, carmustine, cisplatin, cyclophosphamide, dexamethasone, etoposide, gemcitabine hydrochloride, melphalan, paclitaxel, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostate Cancer Recurrent
Interventions: Hydroxychloroquine Sulfate 200Mg Tab; Drug
Lead sponsor: Patrick Hensley; Other
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions: Capecitabine, Celecoxib, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Radiation Therapy, Stereotactic Radiosurgery, Therapeutic Conventional Surgery; Drug · Radiation · Other + 1 more
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma
Interventions: Therapeutic Hydrocortisone, Cytarabine, Dexamethasone, Methylprednisolone, Cyclophosphamide, Axicabtagene Ciloleucel, Brexucabtagene Autoleucel; Drug · Biological
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage IVB Cervical Cancer
Interventions: Bevacizumab, Cisplatin, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration, Topotecan Hydrochloride; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 541
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 351 more

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Diseases, Prostate Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: doxorubicin hydrochloride, motexafin gadolinium; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Madison, Wisconsin

Conditions: Cytomegalovirus Positive, Glioblastoma, Gliosarcoma, Malignant Glioma, Recurrent Brain Neoplasm, Recurrent Glioblastoma
Interventions: Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes, Laboratory Biomarker Analysis, Temozolomide, Therapeutic Conventional Surgery; Biological · Other · Drug + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Male Breast Cancer, Recurrent Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: paclitaxel, bavituximab, laboratory biomarker analysis, pharmacological study; Drug · Biological · Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Carcinoma, Squamous Cell of the Head and Neck
Interventions: REOLYSIN, Carboplatin, Paclitaxel, Placebo; Biological · Drug
Lead sponsor: Oncolytics Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 21
States / cities: Birmingham, Alabama • Tucson, Arizona • Burbank, California + 18 more

Conditions: Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck
Interventions: Cemiplimab-Rwlc; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Tucson, Arizona • Tampa, Florida

Search by objective public record fields.

Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma

Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Tryptophan Metabolism in Human Brain Tumors

Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas

Stereotactic Body Radiation Therapy or Intensity Modulated Radiation/Proton Therapy in Treating Patients With Recurrent Head and Neck Cancer

Arsenic Trioxide in Treating Men With Germ Cell Cancer

Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS

Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.

IM-862 in Treating Patients With Recurrent Ovarian Cancer

Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy

A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma

Bone Marrow Transplant in Treating Patients With Hematologic Cancers

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer

A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer

Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma

Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma

Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer

Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers

Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC